226 related articles for article (PubMed ID: 24860838)
21. Serum autoantibodies against a panel of 15 tumor-associated antigens in the detection of ovarian cancer.
Sun H; Shi JX; Zhang HF; Xing MT; Li P; Dai LP; Luo CL; Wang X; Wang P; Ye H; Li LX; Zhang JY
Tumour Biol; 2017 Jun; 39(6):1010428317699132. PubMed ID: 28618923
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of a panel of tumor-associated antigens in breast cancer.
Pagaza-Straffon C; Marchat LA; Herrera L; Díaz-Chávez J; Avante MG; Rodríguez YP; Arreola MC; López-Camarillo C
Cancer Biomark; 2020; 27(2):207-211. PubMed ID: 31839604
[TBL] [Abstract][Full Text] [Related]
23. Autoantibody signatures as biomarkers to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate specific antigen.
O'Rourke DJ; DiJohnson DA; Caiazzo RJ; Nelson JC; Ure D; O'Leary MP; Richie JP; Liu BC
Clin Chim Acta; 2012 Mar; 413(5-6):561-7. PubMed ID: 22146597
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera.
Lu H; Ladd J; Feng Z; Wu M; Goodell V; Pitteri SJ; Li CI; Prentice R; Hanash SM; Disis ML
Cancer Prev Res (Phila); 2012 Aug; 5(8):1036-43. PubMed ID: 22715141
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of diagnostic value in using a panel of multiple tumor-associated antigens for immunodiagnosis of cancer.
Wang P; Song C; Xie W; Ye H; Wang K; Dai L; Zhang Y; Zhang J
J Immunol Res; 2014; 2014():512540. PubMed ID: 24822225
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of serum autoantibody levels in the diagnosis of ovarian endometrioma.
Yi YC; Wang SC; Chao CC; Su CL; Lee YL; Chen LY
J Clin Lab Anal; 2010; 24(5):357-62. PubMed ID: 20872572
[TBL] [Abstract][Full Text] [Related]
28. MMP26: A potential biomarker for prostate cancer.
Cheng T; Li F; Wei R; Lv MQ; Zhou Y; Dai Y; Yuan Y; Jiang GY; Ma D; Gao QL
J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):891-894. PubMed ID: 29270749
[TBL] [Abstract][Full Text] [Related]
29. A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases.
Xie C; Kim HJ; Haw JG; Kalbasi A; Gardner BK; Li G; Rao J; Chia D; Liong M; Punzalan RR; Marks LS; Pantuck AJ; de la Taille A; Wang G; Mukouyama H; Zeng G
J Transl Med; 2011 Apr; 9():43. PubMed ID: 21504557
[TBL] [Abstract][Full Text] [Related]
30. Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer.
Khan S; Jutzy JM; Valenzuela MM; Turay D; Aspe JR; Ashok A; Mirshahidi S; Mercola D; Lilly MB; Wall NR
PLoS One; 2012; 7(10):e46737. PubMed ID: 23091600
[TBL] [Abstract][Full Text] [Related]
31. Combination of Autoantibody Signature with PSA Level Enables a Highly Accurate Blood-Based Differentiation of Prostate Cancer Patients from Patients with Benign Prostatic Hyperplasia.
Leidinger P; Keller A; Milchram L; Harz C; Hart M; Werth A; Lenhof HP; Weinhäusel A; Keck B; Wullich B; Ludwig N; Meese E
PLoS One; 2015; 10(6):e0128235. PubMed ID: 26039628
[TBL] [Abstract][Full Text] [Related]
32. Detection of autoantibodies to multiple tumor-associated antigens in the immunodiagnosis of ovarian cancer.
Li L; Wang K; Dai L; Wang P; Peng XX; Zhang JY
Mol Med Rep; 2008; 1(4):589-94. PubMed ID: 20523766
[TBL] [Abstract][Full Text] [Related]
33. Discovery and Validation of Serum Autoantibodies Against Tumor-Associated Antigens as Biomarkers in Gastric Adenocarcinoma Based on the Focused Protein Arrays.
Yang Q; Qin J; Sun G; Qiu C; Jiang D; Ye H; Wang X; Dai L; Zhu J; Wang P; Zhang J
Clin Transl Gastroenterol; 2020 Dec; 12(1):e00284. PubMed ID: 33346593
[TBL] [Abstract][Full Text] [Related]
34. Autoantibody response to a novel tumor-associated antigen p90/CIP2A in breast cancer immunodiagnosis.
Liu X; Chai Y; Li J; Ren P; Liu M; Dai L; Qian W; Li W; Zhang JY
Tumour Biol; 2014 Mar; 35(3):2661-7. PubMed ID: 24399648
[TBL] [Abstract][Full Text] [Related]
35. Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma.
Zhang JY; Megliorino R; Peng XX; Tan EM; Chen Y; Chan EK
J Hepatol; 2007 Jan; 46(1):107-14. PubMed ID: 17067715
[TBL] [Abstract][Full Text] [Related]
36. Presence of PSA auto-antibodies in men with prostate abnormalities (prostate cancer/benign prostatic hyperplasia/prostatitis).
Lokant MT; Naz RK
Andrologia; 2015 Apr; 47(3):328-32. PubMed ID: 24620795
[TBL] [Abstract][Full Text] [Related]
37. A panel of autoantibodies as potential early diagnostic serum biomarkers in patients with cervical cancer.
Huangfu M; Xu S; Li S; Sun B; Lee KH; Liu L; Sun S
Tumour Biol; 2016 Jul; 37(7):8709-14. PubMed ID: 26738866
[TBL] [Abstract][Full Text] [Related]
38. Comparison of prostate specific antigen, prostate specific membrane antigen, and LNCaP-based enzyme-linked immunosorbent assays in prostatic cancer patients and patients with benign prostatic enlargement.
Murphy GP; Holmes EH; Boynton AL; Kenny GM; Ostenson RC; Erickson SJ; Barren RJ
Prostate; 1995 Mar; 26(3):164-8. PubMed ID: 7534919
[TBL] [Abstract][Full Text] [Related]
39. Mini-array of multiple tumor-associated antigens (TAAs) in the immunodiagnosis of breast cancer.
Ye H; Sun C; Ren P; Dai L; Peng B; Wang K; Qian W; Zhang J
Oncol Lett; 2013 Feb; 5(2):663-668. PubMed ID: 23420714
[TBL] [Abstract][Full Text] [Related]
40. Tissue polypeptide-specific antigen: a discriminative parameter between prostate cancer and benign prostatic hypertrophy.
Marrink J; Oosterom R; Bonfrer HM; Schröder FH; Mensink HJ
Eur J Cancer; 1993; 29A(4):570-1. PubMed ID: 7679580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
